Oncology and hematology

Oncology and hematology: achieving fast price reimbursement approval and rapid market penetration

The emergence of technologies such as CAR T-cells and use of combinations or sequences of innovative agents presents unique challenges for your asset. We can provide the experience and insight needed to maximize your pricing and reimbursement opportunities.

 

More than half of our consulting work is in oncology, including some of the most innovative products coming to market.

 

Innovative and pragmatic solutions to get the best pricing and reimbursement outcomes for your oncology assets

 

We understand the trade-offs between providing early access to innovative therapies and payers’ calls for proven value and a strong evidence base.

 

Examples of the disease areas we have worked in include:

  • solid tumors, such as breast, gastric, kidney, lung, and prostate cancer
  • leukemia, lymphoma, and myeloma
  • central nervous system tumors.

Accelerate market access and competitive advantage for your oncology asset

 

PRMA Consulting provide you with cutting-edge pricing and reimbursement solutions. Our creative recommendations, strategic insights, and in-depth research are clearly written and presented, delivered on time and on budget. Our depth of experience within oncology and access to a multidisciplinary network of global advisors means that we will come to your project with a specialist understanding of the issues involved.

Request a call

The accomplishment is absolutely exceptional. From the advisory boards, to the GVD development, to the modeling efforts and numerous projects, your support and partnership has been excellent.

Director, Top-20 global biopharma company

You have a vision; we are the consulting partner that will get you there.
We would be delighted to have a confidential conversation about your market access needs.